About Invati
Invati is a company based in Kolkata (India) founded in 2016 by Mukeshh Agarwal. Invati has raised $5.43 million across 1 funding round from investors including Himadri Chemicals and Industries. The company has 34 employees as of February 19, 2025. Invati operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Kolkata, India
- Employees 34 as on 19 Feb, 2025
- Founders Mukeshh Agarwal
-
Sectors
TechnologyAgriculture Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Invati Creations Private Limited
- Date of Incorporation 14 Sep, 2016
- Jurisdiction Kolkata, West Bengal, India
-
Annual Revenue
$638.52 K (USD)14312.35as on Mar 31, 2024
-
Net Profit
$163.6 K (USD)18696.72as on Mar 31, 2024
-
EBITDA
$247.57 K (USD)7606.53as on Mar 31, 2024
-
Total Equity Funding
$5.43 M (USD)
in 1 rounds
-
Latest Funding Round
$5.43 M (USD), Series A
Mar 21, 2024
- Investors
-
Employee Count
34
as on Feb 19, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Invati
Invati has successfully raised a total of $5.43M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.43 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Invati
Invati has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Himadri Chemicals and Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufactures coal tar and basic industrial chemicals.
|
Locked | Locked | Locked |
Investor details for Invati
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Invati
Investment portfolio details for Invati
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Invati
Detailed financials for Invati
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Invati Comparisons
Peer comparison for Invati
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Invati
Invati operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Invati
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Invati
Complete news archive for Invati
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Invati
Invati was founded in 2016 and raised its 1st funding round 8 years after it was founded.
Invati is headquartered in Kolkata, India. It is registered at Kolkata, West Bengal, India.
Mukeshh Agarwal is the current CEO of Invati. They have also founded this company.
Invati is a funded company, having raised a total of $5.43M across 1 funding round to date.
As of Feb 19, 2025, the latest employee count at Invati is 34.
Annual revenue of Invati is $638.52K as on Mar 31, 2024.
Invati was founded in 2016 in Kolkata, India, with a focus on nanotechnology applications across agriculture, animal care, poultry, and pharmaceuticals. Mineral nutrition solutions for chickens are provided, alongside research and development of nano-based anticancer drug molecules. Pharmacy products and food additives are also developed to support these sectors. Operations emphasize innovation in nano-formulations for enhanced efficacy in targeted applications.
Invati's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Invati has 1 investor. Key investors include Himadri Chemicals and Industries.